Newron Pharmaceuticals SpA - Company Profile
Powered by 
All the sales intelligence you need on Newron Pharmaceuticals SpA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Newron Pharmaceuticals SpA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Newron Pharmaceuticals SpA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Newron Pharmaceuticals SpA (Newron) is a biopharmaceutical company. It focuses on the development of novel therapies for diseases of the central and peripheral nervous system. The company’s marketed the product, Xadago (safinamide), which is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain and Evenamide (NW-3509) for the treatment of schizophrenia. The company's main activities include the research and development of innovative treatments for central nervous system disorders and pain management. It has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. The company has an international presence, with products approved in countries including Switzerland, the US, Australia, Canada, and Japan. Newron is headquartered in Bresso, Milan, Italy.
Headquarters
Italy
Address
Via Antonio Meucci 3, Bresso, 20091
Website
www.newron.com
Telephone
39 02 6103461
No of Employees
22
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NWRN (SWF)
Revenue (2024)
$55.6M
467.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
197.7%
(2024 vs 2023)
Market Cap*
$316.0M
Net Profit Margin (2024)
XYZ
117.2%
(2024 vs 2023)
* As of and is in US$
Newron Pharmaceuticals SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed Product: | Xadago |
| Xadago (Safinamide) - Parkinson’s Disease | |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In May, the company received regulatory approval for the pivotal Phase III ENIGMA-TRS program with evenamide as an add-on therapy in patients with treatment-resistant schizophrenia (TRS). |
| 2025 | Contracts/Agreements | In January, the company entered into a licence agreement with Myung to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, an add-on therapy for treatment-resistant schizophrenia. |
| 2024 | Contracts/Agreements | In December, the company entered into an agreement with EA Pharma Co., Ltd. to develop, manufacture, and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated Asian territories. |
Competitor Comparison
| Key Parameters | Newron Pharmaceuticals SpA | Neurocrine Biosciences Inc | Santhera Pharmaceuticals Holding AG | Silence Therapeutics Plc | AC Immune SA |
|---|---|---|---|---|---|
| Headquarters | Italy | United States of America | Switzerland | United Kingdom | Switzerland |
| City | Bresso | San Diego | Pratteln | London | Lausanne |
| State/Province | - | California | - | England | - |
| No. of Employees | 22 | 2,000 | 79 | 115 | 133 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chris Martin | Chairman | Executive Board | 2025 | - |
| Stefan Weber | Chief Executive Officer; Director | Executive Board | 2012 | - |
| Roberto Galli | Chief Financial Officer | Senior Management | 2023 | - |
| Ravi Anand | Chief Medical Officer | Senior Management | 2005 | - |
| Dennis Dionne | Vice President - Commercial Affairs | Senior Management | 2017 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer